$2B Acquisition Expands Incyte's Blood Disorder Pipeline
Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment
Positive
Importance
8
Price
$102.83
Mkt Cap
$20.544B
52W Low
$66.74
52W High
$112.29
52W Position
54% above low
Off High
8.4% below high
Rel. Volume
Market data snapshot near publication time
INCY sits 54% above its 52-week low of $66.74.
Summary
Incyte announced it will acquire Vega Therapeutics for up to $2 billion, significantly expanding its pipeline for blood disorder therapies. This strategic acquisition strengthens Incyte's position in a key therapeutic area. The article also noted Johnson & Johnson's previously reported $1 billion acquisition of Firefly Bio to expand its oncology pipeline.
At the time of this announcement, INCY was trading at $102.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5B. The 52-week trading range was $66.74 to $112.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.
Price Chart
INCY - Latest Insights
INCY
Oct 29, 2026, 4:03 PM EDT
Price at Filing:
$116.80
Real-time Price:
$122.27
Change:
+$5.47 (+5%)
Market Cap:
$24.923B
INCY
Oct 29, 2026, 11:07 AM EDT
Price at Filing:
$115.20
Real-time Price:
$122.27
Change:
+$7.07 (+6%)
Market Cap:
$24.923B
INCY
Oct 29, 2026, 7:00 AM EDT
Price at Filing:
$117.76
Real-time Price:
$122.27
Change:
+$4.51 (+4%)
Market Cap:
$24.923B
INCY
Aug 31, 2026, 4:34 PM EDT
Price at Filing:
$123.22
Real-time Price:
$122.27
Change:
-$0.950 (-0.77%)
Market Cap:
$24.923B
INCY
Jul 29, 2026, 6:00 AM EDT
Price at Filing:
$119.00
Real-time Price:
$122.27
Change:
+$3.27 (+3%)
Market Cap:
$24.923B